PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Cosmetic and skin

GHK-Cu

Also written as: Copper tripeptide-1, Prezatide copper, Glycyl-L-histidyl-L-lysine copper(II), GHK copper, Tripeptide-copper complex (TCC), Iamin (name of an older wound gel that contained it)

GHK-Cu is a small copper-binding peptide found naturally in human blood; it has decades of cell and animal research and a few small human studies of creams and gels, but we found no published human trial of injected GHK-Cu on its own.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • A three-amino-acid peptide that binds copper and occurs naturally in human blood. It is widely used as a cosmetic ingredient.
  • All the human evidence found is for creams, gels and dressings on the skin. The trials are small and the results are mixed.
  • One 1994 gel trial in diabetic foot ulcers was positive. An 86-patient trial in leg ulcers found the copper-peptide cream no better than an inactive cream.
  • No published human trial of injected GHK-Cu on its own was found.
  • The often-quoted claim that it "resets" thousands of genes comes from a computer analysis of cell-line data, not from a study in people.
  • It is not an FDA-approved drug. Only GHK-Cu for non-injectable use is in the FDA's Category 1 for compounding. GHK-Cu for injection is not.
  • It is not named on the anti-doping Prohibited List, but that does not mean it is permitted: class S0 covers substances with no approval for human therapeutic use, and none was found for GHK-Cu.

What it is

GHK is a tripeptide. That means it is a chain of just three amino acids (the building blocks of proteins): glycine, histidine and lysine. It was first found in human blood. GHK holds on tightly to copper. When one copper(II) ion is attached, the pair is called GHK-Cu. Researchers who isolated GHK from plasma found it travelling with roughly equal amounts of copper, and showed that it readily forms complexes with copper(II).

More on what it is and where it came from

GHK-Cu is best known as a skincare ingredient, where it is usually listed as copper tripeptide-1. Reviews of the research note that it appears in many cosmetic products even though few clinical studies of those products have been published. In the 1990s it was also made into a wound gel and dressings, which were tested in people with skin ulcers.

It is not an approved medicine. The human studies that exist put it on the skin. Almost everything said about injecting it comes from studies in cells and animals, not people.

GHK was discovered by the American biochemist Loren Pickart in 1973. Working with human blood, he and M. M. Thaler reported in Nature New Biology a 'tripeptide in human serum' that, in the words of the paper's title, prolonged the survival of normal liver cells and stimulated growth in neoplastic (cancerous) liver. In 1977 the peptide was identified as glycyl-histidyl-lysine. In 1980 Pickart and colleagues reported that it is found together with copper and may help carry copper into cells. Pickart later worked at a skincare company, Skin Biology, and co-wrote many of the reviews on the peptide. His reviews state that the level of GHK in blood plasma is about 200 nanograms per millilitre at age 20 and about 80 by age 60. Those reviews do not cite a published data paper for the two figures, so they should be read as the discoverer's own reported numbers.

How it is thought to work

In cell studies, GHK-Cu made fibroblasts (the skin cells that build connective tissue) produce more collagen and more glycosaminoglycans, the water-holding sugar chains that sit between cells. The effect appeared at very low concentrations and faded at higher ones. The three-letter GHK sequence is also found inside type I collagen, so researchers have suggested the peptide may be released when tissue is damaged and act as a local repair signal. This is a proposal, not a proven mechanism in people.

More on how it works

A second idea is that GHK works mainly as a copper carrier. Copper is needed by several enzymes, and early cell work suggested GHK helps cells take copper up.

A third idea comes from computer analysis of gene activity. Using a public database called the Connectivity Map, which records how cancer cell lines respond to many compounds, researchers reported that GHK shifted the activity of a large share of the genes measured, and that its pattern was the opposite of the pattern seen in damaged emphysema lung tissue. These are findings from cell lines and database comparisons. The authors of the gene analysis themselves wrote that there is not yet enough information to turn gene profiles into real biological effects.

What is established in people

All the human evidence we found is for GHK-Cu put on the skin, as creams, serums, gels or dressings. The trials are small and their results are mixed: one 1994 gel trial in diabetic foot ulcers was positive, an 86-patient trial in leg ulcers found the copper-peptide cream no better than an inactive cream, and a 13-patient laser study found no measurable benefit. The cosmetic studies behind most wrinkle and skin-density claims were conference posters or appeared in journals outside PubMed. We found no published human trial of injected GHK-Cu on its own; a search of ClinicalTrials.gov on 18 November 2026 found four registered studies matching GHK-Cu or copper peptide search terms, and none of them tests an injection of GHK-Cu.

What the studies found

14 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2018

    Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study

    The authors reported less hair fall on a pull test in 83% of patients and a higher hair count at one year, and described the treatment as well tolerated.

    Full finding, who was studied, and limits

    Who: 1,000 patients with hair loss given scalp injections of a mixture of five growth factors plus copper tripeptide-1; open-label, one group, no comparison group

    The authors reported less hair fall on a pull test in 83% of patients and a higher hair count at one year, and described the treatment as well tolerated.

    Read with care: This is the only human injection study we found that includes a copper tripeptide, and it cannot tell us anything about GHK-Cu itself: it was a mixture of six ingredients, injected into the scalp skin, with no control group and no blinding. The abstract gives no side-effect counts.

    Journal of Cosmetic and Laser Therapy · pubmed.ncbi.nlm.nih.gov

  2. Human trial2006

    Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

    No significant difference in how fast redness faded.

    Full finding, who was studied, and limits

    Who: 13 patients who completed a randomised study after laser skin resurfacing around the mouth, using after-care with or without GHK-Cu; assessed by blinded raters and computer analysis at 12 weeks

    No significant difference in how fast redness faded. No objective difference in wrinkles or skin quality between the groups. Patients using GHK-Cu did report higher satisfaction with their skin (P = .04).

    Read with care: Only 13 patients. The measured outcomes showed no benefit; only the patients' own rating favoured GHK-Cu.

    Archives of Facial Plastic Surgery · pubmed.ncbi.nlm.nih.gov

  3. Human trial1994

    Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper

    For ulcers on the sole of the foot, the median area closed was 98.5% with the copper-peptide gel and 60.8% with the gel base.

    Full finding, who was studied, and limits

    Who: People with diabetic nerve-damage foot ulcers, in a multicentre, randomised, evaluator-blinded trial of a GHK-Cu gel (Iamin Gel) against the gel base alone; the abstract does not state how many patients took part

    For ulcers on the sole of the foot, the median area closed was 98.5% with the copper-peptide gel and 60.8% with the gel base. For larger ulcers the figures were 89.2% closed versus 10.3% larger. Infections occurred in 7% of the treated group and 34% of the comparison group. The authors said the gel had to be started straight after the wound was cleaned to work best.

    Read with care: A topical wound gel, not an injection. The abstract gives no patient numbers or trial length. We did not find a published larger trial that confirmed it.

    Wound Repair and Regeneration · pubmed.ncbi.nlm.nih.gov

  4. Human trial1992

    A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

    A negative result for the copper peptide.

    Full finding, who was studied, and limits

    Who: 86 patients with venous leg ulcers who completed the trial, randomised to a copper-tripeptide cream, a silver sulfadiazine cream, or an inactive cream

    A negative result for the copper peptide. The silver cream shrank ulcers significantly more than either of the others. The copper-tripeptide cream did no better than the inactive cream.

    Read with care: One trial in one type of ulcer. It is the largest human trial with a stated size that we found, and it did not show a benefit.

    Journal of Vascular Surgery · pubmed.ncbi.nlm.nih.gov

  5. Review2026

    The Regenerative Potential of GHK-Cu in Aesthetic Medicine

    The preclinical studies reported more connective-tissue production, new blood vessel growth and less inflammation.

    Full finding, who was studied, and limits

    Who: A systematic review of studies up to March 2026: 20 studies in total, of which 18 were preclinical (cells or animals) and 2 were randomised trials in people

    The preclinical studies reported more connective-tissue production, new blood vessel growth and less inflammation. The two human trials reported better patient satisfaction after laser treatment and smaller wrinkles than control. The authors described the evidence as variable in quality, with few well-designed trials.

    Read with care: Only two human trials qualified, both of products put on the skin. The review drew a published comment titled 'Mechanistic Plausibility Should Not Be Conflated With Clinical Validation of GHK-Cu', which we could not open.

    Aesthetic Surgery Journal · pubmed.ncbi.nlm.nih.gov

  6. Review2014

    GHK and DNA: resetting the human genome to health

    The authors reported that GHK raised or lowered the activity of 31.2% of the genes measured by 50% or more.

    Full finding, who was studied, and limits

    Who: A re-analysis of public Connectivity Map data: three GHK gene-activity profiles from two human cancer cell lines (PC3 prostate and MCF7 breast), covering 13,424 genes

    The authors reported that GHK raised or lowered the activity of 31.2% of the genes measured by 50% or more. This is the source of the common claim that GHK affects thousands of genes.

    Read with care: A computer analysis of two cancer cell lines, written by the peptide's discoverer and colleagues at a skincare company. No human trial results. The authors themselves wrote that there is still not enough information to translate gene profiling data into biological effects. The paper's introduction and methods give slightly different percentages (32.1% and 31.2%).

    BioMed Research International · pmc.ncbi.nlm.nih.gov

  7. Animal study2015

    Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction

    At 6 weeks the GHK-Cu groups had less knee looseness than the salt-water group.

    Full finding, who was studied, and limits

    Who: 72 rats that had knee ligament reconstruction surgery, randomised to injections of salt water or one of two strengths of GHK-Cu into the knee joint (24 per group)

    At 6 weeks the GHK-Cu groups had less knee looseness than the salt-water group. By 12 weeks the difference was gone. Graft strength, walking pattern and tissue scores did not differ between groups. The authors concluded the benefit did not last after treatment stopped.

    Read with care: Rats. This is one of the few studies of injected GHK-Cu, and the effect was temporary.

    Journal of Orthopaedic Research · pubmed.ncbi.nlm.nih.gov

  8. Animal study2013

    Effects of topical copper tripeptide complex on wound healing in an irradiated rat model

    A negative result.

    Full finding, who was studied, and limits

    Who: Rats given radiation to the back and then skin-flap surgery; 13 treated with GHK-Cu gel and 10 with a plain ointment were analysed

    A negative result. GHK-Cu gel made no difference to how much of the flap lost its blood supply, to the number or size of blood vessels, or to a growth-factor marker, compared with the plain ointment.

    Read with care: Rats, small groups, one model of radiation-damaged skin. Included here because it tempers the positive animal studies.

    Otolaryngology - Head and Neck Surgery · pubmed.ncbi.nlm.nih.gov

  9. Animal study2003

    The effect of topical tripeptide-copper complex on healing of ischemic open wounds

    After 13 days, wound area had shrunk by 64.5% with the copper-peptide gel, 45.6% with the vehicle and 28.2% with no treatment.

    Full finding, who was studied, and limits

    Who: 24 adult male rats with small open wounds made in skin with poor blood supply, split into gel, vehicle (gel without the peptide) and untreated groups

    After 13 days, wound area had shrunk by 64.5% with the copper-peptide gel, 45.6% with the vehicle and 28.2% with no treatment. Treated wounds also had lower levels of some inflammation and tissue-breakdown markers.

    Read with care: Rats, 24 animals, 13 days. The vehicle gel alone also did better than no treatment.

    Veterinary Surgery · pubmed.ncbi.nlm.nih.gov

  10. Animal study1993

    In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds

    Chambers given GHK-Cu collected more tissue, protein, collagen and glycosaminoglycans than control chambers.

    Full finding, who was studied, and limits

    Who: Rats with small wound chambers placed under the skin of the back; the chambers were injected with GHK-Cu or salt water

    Chambers given GHK-Cu collected more tissue, protein, collagen and glycosaminoglycans than control chambers. Collagen production rose about twice as much as other protein production. A different tripeptide used as a control had no significant effect.

    Read with care: Rats, with the peptide placed directly into a wound chamber. The abstract does not give the number of animals.

    Journal of Clinical Investigation · pubmed.ncbi.nlm.nih.gov

  11. Cell study2012

    A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK

    The team found 127 genes whose activity tracked with how badly each lung region was damaged.

    Full finding, who was studied, and limits

    Who: Lung tissue samples from 8 human lungs (6 from people with severe COPD, 2 donor lungs; 63 samples analysed), a computer search of the Connectivity Map database, and lung fibroblasts from former smokers grown in the lab

    The team found 127 genes whose activity tracked with how badly each lung region was damaged. A database search picked out GHK as a compound whose gene pattern ran the opposite way. In the lab, GHK restored the ability of fibroblasts from COPD lungs to contract and remodel collagen.

    Read with care: No person or animal was given GHK in this study. The Connectivity Map data came from cancer cell lines. The paper does not say whether the copper-bound or copper-free form was used. The authors said the effect on disease still needs study.

    Genome Medicine · pmc.ncbi.nlm.nih.gov

  12. Cell study1992

    Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+

    GHK-Cu increased production of glycosaminoglycans, mainly dermatan sulfate and heparan sulfate.

    Full finding, who was studied, and limits

    Who: Normal human fibroblasts grown in culture

    GHK-Cu increased production of glycosaminoglycans, mainly dermatan sulfate and heparan sulfate. Hyaluronic acid production did not change. The effect rose and then fell back toward normal as the concentration went up.

    Read with care: Cells in a dish. The effect disappeared at higher concentrations, so more was not better.

    Life Sciences · pubmed.ncbi.nlm.nih.gov

  13. Cell study1988

    Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+

    GHK-Cu increased the amount of collagen the cells made, at very low concentrations, without changing the number of cells.

    Full finding, who was studied, and limits

    Who: Fibroblasts (connective-tissue cells) grown in culture

    GHK-Cu increased the amount of collagen the cells made, at very low concentrations, without changing the number of cells. The authors pointed out that the GHK sequence sits inside type I collagen and could be released at wound sites.

    Read with care: Cells in a dish. It shows a possible mechanism, not a benefit in people.

    FEBS Letters · pubmed.ncbi.nlm.nih.gov

  14. Cell study1973

    Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver

    This is the discovery report.

    Full finding, who was studied, and limits

    Who: Normal liver cells and neoplastic (cancerous) liver, exposed to a factor isolated from human serum. The PubMed record has no abstract, so the experimental details could not be confirmed.

    This is the discovery report. As its title states, a tripeptide from human serum helped normal liver cells survive longer in culture and stimulated the growth of neoplastic (cancerous) liver cells.

    Read with care: A laboratory study from 1973. Only the title-level finding could be confirmed. Note that the same paper reports stimulated growth in cancerous liver; a 1980 follow-up by the same authors reported that the peptide with copper or iron stimulated the growth of liver cancer cells in culture. What that means for people is unknown.

    Nature New Biology · pubmed.ncbi.nlm.nih.gov

Safety findings

  • FDA has said that compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity (an unwanted immune reaction), because the peptide may clump together and because of peptide-related impurities. FDA also says there are limited data in humans to inform safety. Source: fda.gov
  • There are no human safety data for injected GHK-Cu on its own that we could find. A 2026 review of 11 peptides sold directly to the public, including GHK-Cu, concluded that human safety data are scarce and that serious harm is possible. Source: pubmed.ncbi.nlm.nih.gov
  • On the skin: in a lab model using human skin cells, GHK-Cu was not toxic to the cells and did not raise irritation markers, while two plain copper salts did. This is a cell study, not a human safety trial. Source: pubmed.ncbi.nlm.nih.gov
  • On the skin: the published human trials of creams and gels were small and short, and their abstracts say little about side effects. In the diabetic ulcer trial, infections were less common with the copper-peptide gel than with the comparison gel (7% versus 34%). Long-term safety of daily cosmetic use has not been reported in a controlled trial that we could find. Source: pubmed.ncbi.nlm.nih.gov
3 more safety findings
  • Copper from a copper tripeptide solution passed through human skin samples in a lab diffusion test and also built up in the skin. This shows that copper applied this way can get past the outer skin layer; the test was not done in living people. Source: pubmed.ncbi.nlm.nih.gov
  • Copper context: copper is an essential mineral that the body keeps under tight control. When that control fails, excess copper has been linked to liver disorders and nerve-cell damage, and the most cited mechanism is oxidative damage. No study we found measured how much copper injected GHK-Cu adds to the body or whether it matters. Source: pubmed.ncbi.nlm.nih.gov
  • The 1973 discovery paper reported, in its title, that the tripeptide stimulated growth in cancerous liver, and a 1980 follow-up reported that it stimulated the growth of liver cancer cells in culture when combined with copper or iron. Later computer analyses suggested the opposite kind of effect on cancer-related genes. Neither has been tested in people, so the effect of GHK-Cu on cancer risk is unknown. Source: pubmed.ncbi.nlm.nih.gov

Rules and status

Not an FDA-approved drug. It is sold as a cosmetic ingredient, and cosmetics are not approved by FDA. As of 18 November 2026, GHK-Cu for injection is not in FDA's Category 1 for compounding and is not among the six peptides named in the appendix to the October 2026 HHS peptide policy; only GHK-Cu for non-injectable use is in Category 1.

The full history, with dates

Approval: GHK-Cu is not an approved medicine. It appears on FDA's list of substances nominated for pharmacy compounding. FDA describes that list as covering substances that pharmacies could not otherwise use in compounding under the law. Cosmetics: FDA states that cosmetic products and ingredients, other than colour additives, do not need FDA approval before they are sold. The company selling a cosmetic is legally responsible for its safety, and a product intended to treat or prevent disease is a drug, not a cosmetic, whatever it is called. So a GHK-Cu face cream being on sale says nothing about FDA having reviewed it. Wound dressings: in 1996 and 1997 FDA cleared copper-peptide wound dressings from ProCyte (for example 'Iamin Gel Wound Dressing', K953853) through the 510(k) device route. A device clearance is not a drug approval. Compounding: FDA sorts substances nominated for pharmacy compounding into Category 1 (under evaluation; FDA does not intend to act against compounders who meet its conditions), Category 2 (significant safety risks identified) and Category 3 (not enough information). GHK-Cu for injectable use was placed in Category 2, widely reported as September 2023; FDA's current page confirms it was 'previously in category 2' and gives the reasons (risk of immune reaction from clumping and impurities, and limited human data) but does not show the date. What happened in 2026: in late February 2026 the HHS Secretary was reported to have said that about 14 peptides would be made available again. We found no formal HHS or FDA document for that statement. The formal steps that followed were these. An FDA page dated 15 April 2026 says FDA will hold a Pharmacy Compounding Advisory Committee meeting before the end of February 2027 to discuss GHK-Cu and four other peptides; no date had been posted when we checked on 18 November 2026. In April 2026 the nominations for GHK-Cu were withdrawn by the people who made them. FDA's safety page, dated 22 April 2026, now lists injectable GHK-Cu in a table of substances 'nominated but withdrawn' that were previously in Category 2, with the same safety concerns still listed. Leaving Category 2 this way did not move it into Category 1. Non-injectable GHK-Cu was removed from Category 1 on 22 April 2026, then added back in the list updated 14 May 2026 after one nominator said on 5 May that it had meant to withdraw only the injectable route. The July 2026 advisory committee meeting discussed seven other peptides, not GHK-Cu. On 30 October 2026 HHS published a notice in the Federal Register (91 FR 68526) saying it does not intend to take enforcement action over compounding with certain listed peptides while rulemaking continues; the notice says it is interim, creates no rights and is not binding. The notice text does not mention GHK-Cu. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, so GHK-Cu is not among them. Announced versus in effect: nothing has been formally published that puts injectable GHK-Cu back into Category 1 or onto the list of substances pharmacies may compound. An advisory committee discussion has been announced but not yet scheduled, and committee votes are recommendations only.

Source: fda.gov (source dated 2026-05-14)

In sport: Not named on the WADA Prohibited List for 2026 (in force from 1 January 2026) or 2027 (in force from 1 January 2027); neither List contains 'GHK', 'copper' or 'prezatide'. Class S0 (Non-approved substances) prohibits at all times 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use'. So S0 applies to GHK-Cu if it has no approval for human therapeutic use anywhere. This page found none: it is not an approved medicine, and its sale in cosmetics and the 1990s clearance of copper-peptide wound dressings as devices are not drug approvals. Section S2.3 also prohibits growth factors and growth factor modulators 'including, but not limited to' those it names. For 2027 WADA added 'peptides' as a named example in S0, and WADA's 2027 explanatory note says that even if a peptide is not specifically named on the List, 'it may still be prohibited'. WADA's Prohibited List page warns that cosmetic creams may contain prohibited peptides or growth factors under other names. WADA has not published a ruling on GHK-Cu by name that we could find. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
GHK-Cu is proven to reverse skin ageing and rebuild collagen.Cell studies show more collagen production in a dish. In people, the best-controlled published study (13 patients after laser treatment) found no measurable difference in wrinkles or skin quality, only higher patient satisfaction. The larger cosmetic studies usually quoted were conference posters or appeared outside PubMed, and a 2025 review noted a surprising absence of clinical studies for an ingredient this widely used. Source: pubmed.ncbi.nlm.nih.gov
Injected GHK-Cu heals injuries and works as a whole-body anti-ageing treatment.We found no published human trial of injected GHK-Cu on its own. The injection studies are in animals, and in a 72-rat knee surgery study the benefit was temporary and gone by 12 weeks. FDA lists safety concerns for injectable GHK-Cu and says human data are limited. Source: pubmed.ncbi.nlm.nih.gov
GHK-Cu resets thousands of human genes to a younger, healthier state.The figure comes from a computer analysis of public data on two cancer cell lines, in which GHK changed the activity of 31.2% of measured genes by 50% or more. The authors wrote that there is still not enough information to translate gene profiling data into biological effects. No study has shown a gene 'reset' in a living person. Source: pmc.ncbi.nlm.nih.gov
Your GHK level falls with age, so topping it up restores youth.The figures quoted (about 200 ng/mL at age 20 and 80 ng/mL by age 60) appear in reviews by the peptide's discoverer without a citation to a published data set. No trial has tested whether raising GHK levels in older people changes any health outcome. Source: pmc.ncbi.nlm.nih.gov
It is a natural part of the body, so it must be safe.GHK does occur naturally in human plasma. That does not establish that a manufactured, injected product is safe. FDA's concerns are about immune reactions, clumping and impurities in compounded injectable products, and it notes that human safety data are limited. Source: fda.gov
FDA made GHK-Cu legal again in 2026.Not for injection. FDA's list, updated 14 May 2026, puts only 'GHK-Cu (except for injectable routes of administration)' in Category 1. Injectable GHK-Cu left Category 2 because its nominations were withdrawn, not because FDA cleared it, and it was not moved into Category 1. Category 1 is not approval in any case. GHK-Cu remains an unapproved drug. Source: fda.gov
Copper peptides are proven to heal wounds and ulcers in people.Results are mixed. A 1994 gel trial in diabetic foot ulcers was positive, but an 86-patient trial in venous leg ulcers found the copper-tripeptide cream no better than an inactive cream. Animal studies are also mixed: positive in several rat and rabbit wound models, no effect in radiation-damaged rat skin. Source: pubmed.ncbi.nlm.nih.gov
GHK-Cu injections regrow hair.The one human study involved scalp injections of a mixture of five growth factors plus copper tripeptide-1, with no comparison group. It cannot show what, if anything, the copper peptide contributed. Source: pubmed.ncbi.nlm.nih.gov

What a genuine lab report should show

  • Identity by mass spectrometry. The report should state which form was tested, because the expected mass differs: PubChem lists the GHK peptide alone at 340.38 g/mol, the 1:1 copper complex at 402.92 g/mol, and the acetate salt form (two peptides, one copper, with acetic acid) at 862.4 g/mol.
  • Purity by HPLC (a method that separates the peptide from related impurities), with the chromatogram shown and the percentage stated. FDA's stated concern about this compound includes peptide-related impurities.
  • Copper content. This is a copper complex, so a complete report should say how much copper is present and how it was measured (published studies used ICP-MS, a standard method for metals). A report that only confirms the peptide does not confirm that copper is bound in the stated ratio.
  • The CAS number on the report should match the form sold: 89030-95-5 for the copper complex, 49557-75-7 for the copper-free GHK peptide.
  • A batch or lot number, test date and the name of the laboratory, so the report can be traced to the actual material.
  • A lab report describes one batch of a chemical. It is not evidence that the compound is safe or effective in people.

How to read a lab report

What is not known

  • Where do the plasma figures (about 200 ng/mL at age 20, about 80 ng/mL by age 60) come from? Two reviews by the discoverer state them without citing a data paper. We could not find the original measurements.
  • Does injected GHK-Cu do anything useful in people, and is it safe? We found no human trial of injected GHK-Cu on its own, no human dose-finding study, and no human data on immune reactions or on how much copper it adds to the body.
  • The original studies behind the best-known cosmetic claims (Leyden 2002 posters; Abdulghani 1998; Finkley 2005 book chapter) could not be opened. Their size, controls and funding are unverified, and two reviews by the same authors disagree on how long the thigh-skin study lasted.
  • The 1994 diabetic ulcer trial abstract gives no patient numbers. We could not find a published larger follow-up trial of the gel, and do not know from primary sources whether one was run or what it found.
  • The exact date FDA first put injectable GHK-Cu in Category 2 (widely reported as late September 2023) is not shown on FDA's current pages.
  • The reported HHS statement of about 27 February 2026 was not found as a formal HHS or FDA publication. It appears to be known only from news coverage of a media interview.
  • FDA says it will take GHK-Cu to its advisory committee before the end of February 2027. No date was posted when we checked on 18 November 2026. This page needs re-checking when that meeting is scheduled and again after it happens.
  • The discovery paper reported faster growth of cancerous liver cells in culture, while later database analyses suggest effects against cancer-related gene patterns. The real-world effect on cancer risk is unknown.
  • Much of the gene-activity work was done with 'GHK' without saying whether copper was attached, so it is unclear how far it applies to GHK-Cu specifically.
  • A 2026 systematic review states that about 35% of the primary literature involves the discoverer or his co-author at a skincare company, which limits how independent the evidence base is.

Sources

All 50 sources
  1. PubChem: Prezatide copper (GHK-Cu), CID 71587328. pubchem.ncbi.nlm.nih.gov
  2. PubChem: glycyl-L-histidyl-L-lysine (GHK), CID 73587. pubchem.ncbi.nlm.nih.gov
  3. PubChem: Prezatide Copper Acetate, CID 9876021. pubchem.ncbi.nlm.nih.gov
  4. Pickart and Thaler 1973, discovery paper (Nature New Biology). pubmed.ncbi.nlm.nih.gov
  5. Schlesinger, Pickart and Thaler 1977, peptide identified as glycyl-histidyl-lysine (Experientia). pubmed.ncbi.nlm.nih.gov
  6. Pickart and Thaler 1980, GHK found with copper and iron in plasma (J Cell Physiol). pubmed.ncbi.nlm.nih.gov
  7. Pickart et al. 1980, tripeptide may help copper uptake into cells (Nature). pubmed.ncbi.nlm.nih.gov
  8. Maquart et al. 1988, collagen synthesis in fibroblasts (FEBS Lett). pubmed.ncbi.nlm.nih.gov
  9. Wegrowski et al. 1992, glycosaminoglycan synthesis in fibroblasts (Life Sci). pubmed.ncbi.nlm.nih.gov
  10. Maquart et al. 1993, rat wound chambers (J Clin Invest). pubmed.ncbi.nlm.nih.gov
  11. Simeon et al. 2000, glycosaminoglycans and proteoglycans in rat wounds (J Invest Dermatol). pubmed.ncbi.nlm.nih.gov
  12. Canapp et al. 2003, ischemic wounds in rats (Vet Surg). pubmed.ncbi.nlm.nih.gov
  13. Cangul et al. 2006, open wounds in rabbits (Vet Dermatol). pubmed.ncbi.nlm.nih.gov
  14. Gul et al. 2008, wounds in rabbits (Vet Dermatol). pubmed.ncbi.nlm.nih.gov
  15. Swaim et al. 1996, locally injected tripeptide-copper complex in dog pad wounds (Am J Vet Res). pubmed.ncbi.nlm.nih.gov
  16. Parker et al. 2013, no effect in irradiated rat skin flaps (Otolaryngol Head Neck Surg). pubmed.ncbi.nlm.nih.gov
  17. Fu et al. 2015, temporary effect after rat ACL reconstruction (J Orthop Res). pubmed.ncbi.nlm.nih.gov
  18. Campbell et al. 2012, emphysema gene signature and GHK (Genome Med). pmc.ncbi.nlm.nih.gov
  19. Hong et al. 2010, colorectal cancer gene signature and Connectivity Map (Clin Exp Metastasis). pubmed.ncbi.nlm.nih.gov
  20. Pickart, Vasquez-Soltero and Margolina 2014, GHK and DNA (Biomed Res Int). pmc.ncbi.nlm.nih.gov
  21. Pickart, Vasquez-Soltero and Margolina 2015, GHK in skin regeneration review (Biomed Res Int). pmc.ncbi.nlm.nih.gov
  22. Pickart and Margolina 2018, review in light of gene data (Int J Mol Sci). pmc.ncbi.nlm.nih.gov
  23. Mulder et al. 1994, diabetic ulcer gel trial (Wound Repair Regen). pubmed.ncbi.nlm.nih.gov
  24. Bishop et al. 1992, venous ulcer trial, copper peptide no better than placebo (J Vasc Surg). pubmed.ncbi.nlm.nih.gov
  25. Miller et al. 2006, laser-resurfaced skin trial (Arch Facial Plast Surg). pubmed.ncbi.nlm.nih.gov
  26. Kapoor and Shome 2018, scalp injections of a growth-factor mixture (J Cosmet Laser Ther). pubmed.ncbi.nlm.nih.gov
  27. Mokhtar et al. 2026, systematic review (Aesthet Surg J). pubmed.ncbi.nlm.nih.gov
  28. Najafi et al. 2026, systematic review noting thin human evidence and limited independence (Arch Intern Med Res). pubmed.ncbi.nlm.nih.gov
  29. Mortazavi et al. 2025, review noting absence of clinical studies (Bioimpacts). pubmed.ncbi.nlm.nih.gov
  30. Mendias and Awan 2026, safety and efficacy of approved and unapproved peptides (Sports Med). pubmed.ncbi.nlm.nih.gov
  31. Li et al. 2016, skin irritation markers for copper compounds (Sci Rep). pubmed.ncbi.nlm.nih.gov
  32. Hostynek et al. 2010, copper tripeptide penetration of human skin in vitro (Inflamm Res). pubmed.ncbi.nlm.nih.gov
  33. Gaetke et al. 2014, Copper: toxicological relevance and mechanisms (Arch Toxicol). pubmed.ncbi.nlm.nih.gov
  34. ClinicalTrials.gov search (terms used: GHK-Cu, copper tripeptide, copper peptide, prezatide, glycyl-histidyl-lysine; 4 studies on 18 November 2026). clinicaltrials.gov
  35. ClinicalTrials.gov NCT07437586, topical GHK-Cu gel for wound healing (recruiting). clinicaltrials.gov
  36. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated 14 May 2026). fda.gov
  37. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current 22 April 2026). fda.gov
  38. FDA: Bulk Drug Substances Used in Compounding Under Section 503A (category definitions; content current 14 May 2026). fda.gov
  39. FDA: planned Pharmacy Compounding Advisory Committee meeting on GHK-Cu and four other peptides, before end of February 2027 (content current 15 April 2026). fda.gov
  40. FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting (seven other peptides). fda.gov
  41. Federal Register, 16 April 2026: notice of the July 2026 advisory committee meeting (91 FR 20465). govinfo.gov
  42. Federal Register, 30 October 2026: HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526). govinfo.gov
  43. FDA: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated (content current 18 November 2025). fda.gov
  44. FDA 510(k) database: K953853, Iamin Gel Wound Dressing, ProCyte (decision 5 February 1996). accessdata.fda.gov
  45. FDA 510(k) database: K970153, hydrating gel, ProCyte (decision 5 June 1997). accessdata.fda.gov
  46. WADA Prohibited List (searchable 2026 list and FAQ). wada-ama.org
  47. WADA 2026 Prohibited List (in force 1 January 2026; GHK-Cu not named). wada-ama.org
  48. WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
  49. WADA 2027 Prohibited List: summary of major modifications and explanatory notes (S0 and peptides). wada-ama.org
  50. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.